List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Overview
Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Companies Involved in Therapeutics Development
Aviara Pharmaceuticals Inc
C4X Discovery Holdings Plc
DiCE Molecules SV Inc
Genentech USA Inc
Gilead Sciences Inc
Morphic Therapeutic Inc
Polpharma Biologics SA
Progenity Inc
Protagonist Therapeutics Inc
Takeda Pharmaceutical Co Ltd
Zealand Pharma AS
Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Drug Profiles
etrolizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GS-1427 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MORF-057 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PN-943 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PTG-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize Integrin Alpha 4 Beta 1 and Alpha 4 Beta 7 for Inflammatory Bowel Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize Integrin Alpha 4 Beta 7 for Inflammatory Bowel Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize Integrin Alpha4 and Beta7 for Inflammatory Bowel Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vedolizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vedolizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vedolizumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZP-10000 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Dormant Products
Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Discontinued Products
Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Product Development Milestones
Featured News & Press Releases
Sep 07, 2021: Protagonist Therapeutics appoints Scott Plevy, M.D., executive vice president and therapeutic head, gastroenterology
Jul 09, 2021: Morphic reports new data from positive phase 1 study of MORF-057, oral integrin inhibitor candidate for IBD
Jul 02, 2021: Morphic Therapeutic to host analyst and investor call on July 9, 2021
May 28, 2021: Morphic Therapeutic to present positive phase 1 data for MORF-057 at ECCO'21 Virtual Congress
Mar 01, 2021: Morphic reports positive interim results from single ascending dose phase 1 clinical trial of MORF-057
Feb 22, 2021: Morphic Therapeutic to host analyst and investor call on March 1, 2021
Jan 19, 2021: Ready-to-use self-injectable formulation of ENTYVIO (vedolizumab) now available for Canadians for the maintenance treatment of moderately to severely active Crohn's disease and ulcerative colitis
Dec 09, 2020: Takeda's pipeline including vedolizumab has potential to contribute significantly to revenue growth over next decade
Oct 13, 2020: Takeda reports positive interim data from trial of Entyvio
Oct 12, 2020: Morphic announces presentation of new data supporting development of MORF-057 at UEG Week Virtual 2020
Sep 23, 2020: Morphic Therapeutic announces first healthy volunteers dosed in Phase 1 clinical trial of MORF-057
Sep 02, 2020: Update on the U.S. Development Program for the investigational subcutaneous formulation of ENTYVIO (vedolizumab) as a maintenance therapy in adults with moderate to severe Ulcerative Colitis
Aug 11, 2020: Roche announces mixed Phase III results of etrolizumab
Jun 23, 2020: Takeda receives U.S. FDA approval to manufacture ENTYVIO (vedolizumab) drug substance at manufacturing facility in Brooklyn Park, Minnesota
May 08, 2020: European commission approves subcutaneous formulation of Entyvio (Vedolizumab) for use as maintenance therapy in adults with moderately to severely active Ulcerative Colitis or Crohn's Disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Indication, 2021
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pipeline by Aviara Pharmaceuticals Inc, 2021
Pipeline by C4X Discovery Holdings Plc, 2021
Pipeline by DiCE Molecules SV Inc, 2021
Pipeline by Genentech USA Inc, 2021
Pipeline by Gilead Sciences Inc, 2021
Pipeline by Morphic Therapeutic Inc, 2021
Pipeline by Polpharma Biologics SA, 2021
Pipeline by Progenity Inc, 2021
Pipeline by Protagonist Therapeutics Inc, 2021
Pipeline by Takeda Pharmaceutical Co Ltd, 2021
Pipeline by Zealand Pharma AS, 2021
Dormant Projects, 2021
Discontinued Products, 2021

List of Figures
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Top 10 Indications, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021

Companies Mentioned
• Aviara Pharmaceuticals Inc
• C4X Discovery Holdings Plc
• DiCE Molecules SV Inc
• Genentech USA Inc
• Gilead Sciences Inc
• Morphic Therapeutic Inc
• Polpharma Biologics SA
• Progenity Inc
• Protagonist Therapeutics Inc
• Takeda Pharmaceutical Co Ltd
• Zealand Pharma AS